**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 60756

**Manuscript Type:** META-ANALYSIS

**Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis**

Patel TK *et al*. A meta-analysis of remdesivir in COVID-19

Tejas Kamleshbhai Patel, Parvati B Patel, Manish Barvaliya, Vijayalaxmi, Hira Lal Bhalla

**Tejas Kamleshbhai Patel, Vijayalaxmi, Hira Lal Bhalla,** Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Gorakhpur 273008, Uttar Pradesh, India

**Parvati B Patel,** Department of Pharmacology, GMERS Medical College, Gotri, Vadodara 390021, Gujarat, India

**Manish Barvaliya,** Department of Pharmacology, Government Medical College, Bhavnagar, Bhavnagar 364001, Gujarat, India

**Author contributions:** All authors designed the meta-analysis; Patel TK andPatel PB conducted the literature search; Patel TK and Barvaliya M extracted the data; Patel TK,Patel PB andBarvaliya M analyzed the data; all authors interpreted the data; Patel TK wrote the first draft and revised subsequent drafts with input from Patel PB,Barvaliya M,Vijayalaxmi,andBhalla HL.

**Corresponding author: Tejas Kamleshbhai Patel, MD, Associate Professor,** Department of Pharmacology, All India Institute of Medical Sciences, Gorakhpur, Kunraghat, Gorakhpur 273008, Uttar Pradesh, India. dr.tkp2006@yahoo.co.in

**Received:** November 12, 2020

**Revised:** February 16, 2021

**Accepted:** February 25, 2021

**Published online:** February 28, 2021

**Abstract**

BACKGROUND

Remdesivir is a broad-spectrum antiviral drug having in vitroactivity against severe acute respiratory syndrome coronavirus 2 and is currently being used on a compassionate basis outside of clinical trials.

AIM

To analyze the efficacy and safety of remdesivir compared with other interventions in coronavirus disease 2019 (COVID-19) patients.

METHODS

We searched online databases to include randomized controlled trials evaluating the efficacy and safety of remdesivir compared with other interventions in COVID-19 patients. We summarized efficacy and safety data as risk ratios (RRs) with 95% confidence interval (CI) and used Mantel-Haenszel fixed or random-effect models. We estimated the number needed to treat (NNT) to cause one additional outcome. We used the GRADE approach to assess the quality of the evidence for all outcome parameters.

RESULTS

We included four randomized controlled trials. We observed no significant difference in mortality (RR: 0.83; 95%CI: 0.57–1.20; *I*2 = 59%) and rate of ventilation (RR: 0.69; 95%CI: 0.41-1.18; *I*2 = 77%) between remdesivir- and placebo-treated patients. Remdesivir showed higher rates of clinical recovery than placebo (RR: 1.10; 95%CI: 1.04–1.16; *I*2 = 0%; NNT: 14.3). We observed no difference in overall adverse events between remdesivir- and placebo-treated patients (RR: 1.05; 95%CI: 0.86–1.27; *I*2 = 77%). We observed less risk of serious adverse events (RR: 0.75; 95%CI: 0.63–0.89; *I*2 = 0%) in remdesivir- than placebo-treated patients. The GRADE approach suggested moderate quality of evidence for all efficacy and safety outcomes.

CONCLUSION

We observed limited clinical benefit of remdesivir over placebo in the treatment of COVID-19. Our findings could be biased because of the small number of trials.

**Key Words:** COVID-19; SARS-CoV-2; Antiviral; Pneumonia; Remdesivir; Meta-analysis; Systematic review

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Patel TK, Patel PB, Barvaliya M, Vijayalaxmi, Bhalla HL. Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. *World J Meta-Anal* 2021; 9(1): 74-87

URL: https://www.wjgnet.com/2308-3840/full/v9/i1/74.htm

DOI: https://dx.doi.org/10.13105/wjma.v9.i1.74

**Core Tip:** Remdesivir is an antiviral drug having in vitro and in vivo activity against severe acute respiratory syndrome coronavirus 2. United States Food and Drug Administration has granted emergency use authorization for its use in all hospitalized patients. The findings of this meta-analysis suggest remdesivir can enhance clinical recovery without having significant benefits on mortality outcomes. because of lack of any major safety concerns, its use is recommended in the absence of effective antiviral drugs against coronavirus disease 2019.

**INTRODUCTION**

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first described in China. Later it was declared a pandemic by the World Health Organization (WHO). COVID-19 is highly contagious, and is associated with significant morbidity and mortality[1-4]. Currently, there are no definitive proven antiviral treatments for COVID-19. Several potential therapeutic options, including remdesivir, have been evaluated for the treatment of COVID-19[5].

Remdesivir is a broad-spectrum antiviral drug having activity against several RNA viruses, including filoviruses (*e.g.*, Ebola virus, Marburg virus), coronaviruses (*e.g.*, SARS-CoV, Middle East respiratory syndrome coronavirus, and paramyxoviruses (*e.g.*, respiratory syncytial virus, Nipah virus, and Hendra virus). It is a prodrug metabolized within cells into the active nucleoside triphosphate. This nucleoside triphosphate acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrates to selectively inhibit RNA-dependent RNA polymerase resulting in delayed RNA chain termination during the process of viral replication[6,7]. Delayed chain termination at positions I and 3 are key elements of inhibition observed with SARS-CoV, MERS-CoV[6] and SARS-CoV-2 RNA-dependent RNA polymerase complexes[8,9]. An in vitro study by Wang *et al*[10] suggested that remdesivir could achieve a therapeutic working concentration against SARS-CoV-2 in Vero E6 cells. It inhibited virus infection in human liver cancer Huh-7 cells, which are sensitive to SARS-CoV-2[10]. Moreover, prophylactic and therapeutic administration of remdesivir reduced the virus replication, disease severity and lung damage caused by MERS-CoV in the rhesus macaque animal model[11].

The clinical evidence of utility of remdesivir in COVID-19 patients is limited. It is primarily used on a compassionate basis outside of clinical trials in the absence of other available effective treatment options[12,13]. Recently published studies have shown contradictory findings about the efficacy of remdesivir in COVID-19. The adaptive COVID-19 treatment trial (ACTT) trial suggested better clinical recovery and trends of mortality reduction with remdesivir[14], while he WHO solidarity trial did not find a significant reduction in mortality with the use of remdesivir in COVID-19[15]. In this meta-analysis, we aimed to assess the efficacy and safety of remdesivir in COVID-19 patients based on evidence from published randomized controlled clinical trials.

**MATERIALS AND METHODS**

***Literature search***

We searched the clinical studies of remdesivir in COVID-19 patients in PubMed, medrxiv.org, biorxiv.org, mediterranee-infection.com/pre-prints-ihu, LILACS, CNKI and Google Scholar. The PubMed search terms were: (“Remdesivir”) AND (“COVID-19” OR “SARS-CoV-2” OR “Coronavirus”). The last search was run on October 28, 2020. There were no language restrictions for inclusion of the studies.

***Types of participants***

Patients of any age and either sex who had virologically confirmed SARS-CoV-2 infection were included in the analysis.

***Types of studies***

**Inclusion criteria:** (1) Randomized controlled clinical trials; (2) Open labeled or blinded studies; and (3) Comparative trials of remdesivir with any other interventions including placebo.

**Exclusion criteria:** (1)Studies of remdesivir other than SARS-CoV-2; (2) Observational studies, noncomparative studies, case reports; (3) In vitro and animal studies of remdesivir in COVID-19; and (4) Review articles, commentaries, viewpoints, or editorials.

***Types of intervention***

Use of remdesivir in COVID-19 patients irrespective of dose and duration of therapy was considered. All treatment modalities including placebo were considered as the comparator arm.

***Risk of bias assessment***

The methodological characteristics of included studies were assessed through five domains of the revised Cochrane risk of bias assessment tool for randomized controlled clinical trials (ROB-II)[16].

***Data extraction***

We imported the data into a Microsoft Excel 2016 spreadsheet. The extracted data included publication details, study design, study site, demographics of the study population, baseline clinical characteristics, remdesivir dose, duration and mode of administration, comparator, supportive care, and outcome variables (*i.e*. number of deaths, number of patients requiring invasive ventilation, clinical recovery and serious adverse events).

***Types of outcome measures***

**Efficacy outcomes:** The efficacy outcome variables were the RRs of cumulative mortality, composite mortality and ventilation, mechanical ventilation or extracorporeal membrane oxygenation ECMO) rate and clinical recovery rate of remdesivir in comparison with other interventions. In case of multiple time-point estimation of outcomes in the included studies, we used data at the end of study periods. Intention to treat data were used to estimate the efficacy outcomes.

**Safety outcomes:** The safety outcome variables were participants with adverse events (overall, grade 3 or 4, and serious adverse events) in the remdesivir and comparator arms. The safety population was used to estimate the safety outcomes. All patients who received remdesivir and comparator drugs irrespective of per-protocol dose and duration were considered as a safety population and included in the estimation of safety outcomes.

***Data synthesis and meta-analysis***

All outcomes were dichotomous variables. They were summarized as a risk ratio (RR) with 95% confidence interval (CI) using the Mantel-Haenszel method with a fixed- or random-effect model. The selection of meta-analysis model was based on the presence of heterogeneity. The fixed model effect was preferred in the absence of heterogeneity. Heterogeneity was estimated through *I*2. Sensitivity analysis of efficacy and safety outcomes was performed based on risk of bias assessment and study design. The meta-analytic summary was calculated by excluding studies showing “some concern” or high risk of bias as per the ROB-II tool and those with an open-label design.

The pooled risk difference of meta-analytic summary was estimated. It was used to calculate the number needed to treat (NNT) to cause one additional outcome[17]. The GRADE approach was used to analyze the quality of the evidence for each of the efficacy and safety outcomes. It was assessed based on the following parameters: study limitations, inconsistency, indirectness of evidence, imprecision, and publication bias[18,19]. The meta-analysis was conducted with Review Manager version 5.4.1.

**RESULTS**

Of the 2289 retrieved references, we selected 46 publications for full-text evaluation (Figure 1). We included four randomized controlled trials analyzing the effects of remdesivir in COVID-19 patients.

***Characteristics of included studies***

Table 1 shows the general characteristics of the included studies. The included studies used remdesivir as an add-on to the standard care of treatment. Beigel *et al*[14] conducted a double-blind, randomized, placebo-controlled, multicenter study in North America, Europe and Asia; 541 patients were assigned to the remdesivir and 521 to the placebo arms. The treatment arms were comparable at baseline for age, gender, race, median time from symptom onset to randomization, co-morbid conditions and severity status.

The WHO Solidarity Trial Consortium *et al*[15] was a solidarity trial conducted by the WHO. It was a randomized, open label, parallel arm, multicenter study investigating the effect of four repurposed medications (remdesivir, hydroxychloroquine, interferon-β1a, and lopinavir/ritonavir) with local standard care. The comparator of remdesivir was a group of patients with a similar probability of allocation to receive remdesivir, but instead receiving standard care. A total of 2743 patients were assigned to receive remdesivir. The corresponding 2708 patients were assigned to receive local standard care. Both treatment arms were comparable at baseline for age, gender, co-morbidity, bilateral lung lesions, respiratory support and prior impatient days before randomization.

Spinner *et al*[20] conducted a randomized, open-label, placebo-controlled, multicenter study in moderate COVID-19 pneumonia patients at North America, Europe and Asia. A total of 197 patients were assigned to receive remdesivir of 10 d duration, 199 to remdesivir of 5 d duration and 200 to placebo. As all other included studies administered remdesivir for 10 d, we used remdesivir data of 10 d treatment duration only. The treatment arms (remdesivir 10 d and placebo) were comparable at baseline for age, gender, race, co-morbidity, and duration of symptoms before the administration of interventions and duration of hospitalization before the administration of interventions. The placebo-treated group had a higher percentage of patients with baseline oxygen requirement (19% *vs* 13%). Compared with the remdesivir-treated group, a higher percentage of patients in the placebo arm received hydroxychloroquine/chloroquine (45% *vs* 11%), lopinavir/ritonavir (22% *vs* 6%) and azithromycin (31% *vs* 21%).

Wang *et al*[21] conducted a double-blind, randomized, placebo-controlled, multicenter study in China. A total of 158 patients were assigned to receive remdesivir and 78 to receive placebo. Both treatment arms were comparable at baseline for age, gender, body temperature, viral load, oxygen therapy support and co-interventions (interferon alfa-2b, lopinavir/ritonavir or corticosteroid administration). The remdesivir-treated group had a higher percentage of patients with co-morbidities and a faster respiratory rate at baseline. The placebo-treated group had a higher percentage of patients with early symptom onset at baseline.

***Risk of bias in included studies***

Three trials were considered to have a low risk of bias for all the domains of the ROB-II tool (randomization process, effect of assignment to intervention, effect of adhering to intervention, missing outcome data, measurement of the outcome, selection of the reported results and overall risk of bias assessment). Spinner *et al*[20] was considered to have some concerns for the effect of assignment to intervention domain because of imbalance in co-interventions among remdesivir- and placebo-treated patients. Hence, the overall risk of bias was considered to have some concern as per ROB-II tool (Table 2).

***Meta-analytic summary of efficacy outcomes***

**Mortality:** As shown in Figure 2A, we observed no significant difference in the RR of mortality between remdesivir and control patients (RR: 0.83; 95%CI: 0.57–1.20). An *I*2 = 59% suggested a moderate degree of between-trial heterogeneity. The NNT to cause one additional reduction in mortality of COVID-19 patients with remdesivir was 100 (95%CI: −25–100). The GRADE approach suggested moderate quality evidence (Table 3). The sensitivity analysis showed a similar trend in mortality (Table 4).

**Ventilation:** As shown in Figure 2B, we did not observe any significant difference in RR of mechanical ventilation or ECMO between remdesivir and placebo or supportive care treatment (RR: 0.69; 95%CI: 0.41–1.18; *I*2 = 77%) (Figure 2B). The NNT to cause one additional reduction in need of ventilation of COVID-19 patients with remdesivir was 50 (95%CI: −16.7–100). The GRADE approach suggested moderate quality evidence (Table 3). The sensitivity analysis based on study design suggested a trend of benefit with the use of remdesivir (RR: 0.57; 95%CI: 0.41­0.77; *I*2 = 0%).

**Composite mortality and ventilation:** We observed no benefit of remdesivir in reducing the risk of the composite outcome of mortality and ventilation compared with placebo or supportive care (RR: 0.80; 95%CI: 0.58–1.11; *I*2 = 78%) (Figure 2C). This corresponds to an NNT to cause one additional participant to experience mortality and ventilation in COVID-19 patients receiving remdesivir compared with placebo of 25 (95%CI: −12.5–100). The GRADE approach suggested moderate quality evidence (Table 3). The sensitivity analysis based on study design suggested a trend of benefit in composite outcome with the use of remdesivir (RR: 0.69; 95%CI: 0.55–0.86; *I*2 = 10%) (Table 4).

**Clinical recovery:** Three trials reported clinical recovery. Patients treated with remdesivir had higher rates of clinical recovery than those receiving placebo (RR: 1.10; 95%CI: 1.04–1.16; *I*2 = 0%, Figure 3). On sensitivity analysis, the RR was 1.10 (95%CI: 1.02–1.18; *I*2 = 0%). The NNT to cause one additional improvement in clinical recovery was 14.3 (95%CI: 9.1–33.3). GRADE approach evidence quality was moderate. The sensitivity analysis showed a similar trend in clinical recovery outcome.

***Meta-analytic summary of safety outcomes***

**Adverse events:** Three trials reported 520 adverse events in 880 participants of the remdesivir groups and 466 of 794 participants in the placebo-treated groups (Figure 4). There was no significant difference in the RR of adverse events between remdesivir and placebo-treated patients (RR: 1.05; 95%CI: 0.86­1.27; *I*2 = 77%). The sensitivity analysis showed a similar trend in adverse event outcome. GRADE approach evidence quality was moderate.

**Adverse events of grade 3 or 4:** Three trials reported 315 grade 3 or 4 adverse events in 866 participants of the remdesivir groups and 340 of 780 participants in the placebo groups (Figure 5A). Patients receiving remdesivir were 11% less likely to experience grade 3 or 4 adverse events than placebo-treated patients (RR: 0.88; 95%CI: 0.79–0.99; *I*2 = 0%). GRADE approach evidence quality was moderate. The NNT to cause one additional participant to experience fewer serious adverse events compared with placebo, was 20 (95%CI: 11.1–100). The sensitivity analysis did not suggest a reduced risk of adverse events in the remdesivir arm (RR: 0.87; 95%CI: 0.71–1.07; *I*2 = 10%).

**Serious adverse events:** Three trials reported 186 serious adverse events in 880 participants of the remdesivir groups and 201 of 794 participants in the placebo-treated groups (Figure 5B). Participants were 25% less likely to experience serious adverse events in the remdesivir group compared with the placebo-treated group (RR: 0.75; 95%CI: 0.63–0.89); *I*2 = 0%; GRADE approach evidence quality was moderate). On sensitivity analysis, the RR was 0.76 (95%CI: 0.64–0.92; *I*2 = 0%). The NNT to cause one additional participant to experience fewer serious adverse events compared with placebo, was 16.7 (95%CI: 11.1–50). The sensitivity analysis showed a similar trend in this outcome.

**DISCUSSION**

The findings of this pooled analysis suggest a trend of limited clinical benefits with the use of remdesivir in COVID-19 patients. More evidence based on double-blind randomized controlled trials is required to evaluate its benefit in reducing mortality and the need of invasive ventilation in the severe COVID-19 patients.

Currently no effective antiviral drugs are available to treat COVID-19. Only dexamethasone showed a mortality benefit in severe COVID-19 patients requiring respiratory support[22]. During the initial period of the pandemic, remdesivir was used on a compassionate basis outside of randomized controlled trials in COVID-19 patients based on in vitro and animal studies. In May 2020, the Food and Drug Administration (FDA) granted the emergency use authorization to use remdesivir in severe COVID-19 patients. In October 2020, emergency use authorization was extended to all hospitalized patients[23]. Our meta-analysis suggests no major safety concerns with its use. Our findings support the emergency use authorization by the United States FDA in the absence of availability of better antiviral drugs. However, remdesivir alone does not seem to be a promising option. The discovery of better antiviral drug should go beyond it.

Included studies presented earlier findings of efficacy based on randomized controlled trials. Beigel *et al*[14] (the ACTT trial) reported a mortality benefit. Three other studies including the WHO solidarity trial observed no difference at the end of the study period[15,20,21]. In case of ventilatory support requirement, Beigel *et al*[14] suggested a beneficial effect. Two smaller trials observed a trend of reduced risk of ventilation[20,21], while the WHO solidarity trial did not find any difference[15]. A noncomparative study by Antinori *et al*[24], reported 22.2% of the patients on invasive ventilation showed improvement after remdesivir treatment. In case of clinical recovery, three trials reported trends of improvement[14,20,21]. Beigel *et al*[14] and Spinner *et al*[20] found that remdesivir was superior to placebo in shortening of clinical recovery time, whereas Wang *et al*[21] did not find any statistically significant clinical benefit with remdesivir in severe COVID-19 patients. Beigel *et al*[14] found that the median recovery time was shorter in patients treated with remdesivir than it was with placebo treatment (10 d *vs* 15 d), whereas in the study by Wang *et al*[21] the recovery time was 21 d in the remdesivir group compared with 23 d the placebo group. The WHO solidarity trial did not report clinical recovery with the study medications[15]. Moreover, there was a decreased duration of initial hospitalization (12 d *vs* 17 d) and a reduction in the number of days in which patients received oxygen (13 d *vs* 21 d) if they were on oxygen at baseline, in the remdesivir-treated group as compared to placebo. However, it did not reduce the reoccurrence of a need for oxygen[14]. Noncomparative studies by Antinori *et al*[24] and Grein *et al*[25] also observed that remdesivir can provide a greater benefit to patients with pneumonia requiring oxygen therapy or non-invasive ventilation than to those receiving mechanical ventilation. Thus, early intervention with remdesivir can provide increased clinical benefit with fewer adverse events[24]. None of the studies included in the present review focused on virological cure. Severe COVID-19 patients have high viral loads and generally need an longer duration to become negative than those with low viral loads[26,27]. A study by Antinori *et al*[24] found a 100% SARS-COV-2 negative conversion rate with remdesivir, and it occurred after a median period of 12 d (interquartile range 9.25–16.75) after starting the treatment.

Remdesivir has a better or comparable tolerability profile than placebo. The findings of safety analyses should be interpreted cautiously as rare and serious adverse events are usually identified with the widespread use of any drug outside of clinical trials[28,29]. Limited information is available for the use of remdesivir in pregnant women and patients with hepatic or renal impairment[30,31]. This is especially important from the aspect of high prevalence of acute kidney injury during and its associated mortality in hospitalized COVID-19 patients[32]. Abnormal liver function test values are common in COVID-19 patients[33,34].

Our study has several limitations. Although there was a meticulous search to identify published studies on PubMed and Google Scholar as well as preprint versions of studies on Medrxiv and other databases, we could identify only four published randomized trials to date. The findings of this study could indicate trends rather than confirmation due to non-consideration of the impact of co-morbidities and severity status. We could not analyze the impact of remdesivir on virological cure. While this study was under peer-review, few meta-analyses of remdesivir against COVID-19 have been published. The earlier studies included randomized and observational studies[35,36], did not perform sensitivity analyses[37-39] and did not include quality assessment of efficacy and safety parameters as per the GRADE approach[37-39].

**CONCLUSION**

The benefits of remdesivir over placebo were significant only in causing higher rates of clinical cure. Use of remdesivir can be continued on a compassionate basis in the absence of specific antiviral drugs. The evidence is based on only four clinical trials.

**ARTICLE HIGHLIGHTS**

***Research background***

There are no specific antiviral drugs currently available to combat coronavirus disease 2019 (COVID-19) caused by novel virus severe acute respiratory syndrome coronavirus 2. This has promoted the evaluation of various previously approved drugs as an effective treatment for COVID-19. Remdesivir is one such repurposed drug currently under investigation against COVID-19.

***Research motivation***

This study investigated whether remdesivir is an effective and safe option to treat COVID-19 patients.

***Research objectives***

In this study, the authors aimed to provide a meta-analytic summary of the efficacy and safety outcomes in COVID-19 patients with the use of remdesivir as compared with control interventions.

***Research methods***

A literature search was conducted to identify studies published through October 28, 2020. Randomized controlled trials of remdesivir plus any other interventions including placebo were included. The quality assessment of all included studies for methodological characteristics was performed with the revised Cochrane risk of bias assessment tool for randomized controlled clinical trials. The efficacy outcome variables were mortality, need for mechanical ventilation, composite mortality and ventilation and clinical recovery rate. The safety outcome variables were overall adverse events, grade 3 or 4 adverse events and the serious adverse events rate.

***Research results***

We included a total of four randomized controlled trials in this meta-analysis. Three studies were considered to have a low risk and one study was considered to have some concerns in the overall risk of bias assessment. Remdesivir- and placebo-treated patients did not differ in mortality, rate of mechanical ventilation and composite mortality and ventilation rate outcomes. A sensitivity analysis suggested a reduced risk of ventilation and composite mortality and ventilation with remdesivir on exclusion of open-label studies. Remdesivir-treated patients showed higher rates of clinical recovery than placebo-treated patients. Remdesivir and placebo-treated patients did not differ in the overall occurrence of adverse events. Remdesivir-treated patients were at lower risk of grade 3 or 4 adverse events and serious adverse events than placebo-treated patients. The GRADE approach suggested moderate quality of evidence for all efficacy and safety outcomes.

***Research conclusions***

The effect of remdesivir over placebo was not significant for mortality or the rate of ventilation. However, remdesivir may provide higher rates of clinical cure. There are no major safety concerns with the use of remdesivir. Its use can be continued on a compassionate basis in the absence of specific antiviral drugs.

***Research perspectives***

The current evidence is based on four clinical trials only. More evidence based on double-blind randomized controlled trials in different disease-severity populations is required to evaluate the benefits of remdesivir in COVID-19 patients.

**REFERENCES**

1 **Peeri NC**, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? *Int J Epidemiol* 2020; **49**: 717-726 [PMID: 32086938 DOI: 10.1093/ije/dyaa033]

2 **Inciardi RM**, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A, Faggiano P, Gorga E, Lombardi CM, Milesi G, Vizzardi E, Volpini M, Nodari S, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. *Eur Heart J* 2020; **41**: 1821-1829 [PMID: 32383763 DOI: 10.1093/eurheartj/ehaa388]

3 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

4 **Wang D**, Yin Y, Hu C, Liu X, Zhang X, Zhou S, Jian M, Xu H, Prowle J, Hu B, Li Y, Peng Z. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. *Crit Care* 2020; **24**: 188 [PMID: 32354360 DOI: 10.1186/s13054-020-02895-6]

5 **Khan S**, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, Bashir N, Xue M. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. *J Clin Microbiol* 2020; **58** [PMID: 32161092 DOI: 10.1128/JCM.00187-20]

6 **Gordon CJ**, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. *J Biol Chem* 2020; **295**: 6785-6797 [PMID: 32284326 DOI: 10.1074/jbc.RA120.013679]

7 **Tchesnokov EP**, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. *Viruses* 2019; **11** [PMID: 30987343 DOI: 10.3390/v11040326]

8 **Gordon CJ**, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. *J Biol Chem* 2020; **295**: 4773-4779 [PMID: 32094225 DOI: 10.1074/jbc.AC120.013056]

9 **Yin W**, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science* 2020; **368**: 1499-1504 [PMID: 32358203 DOI: 10.1126/science.abc1560]

10 **Wang M**, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; **30**: 269-271 [PMID: 32020029 DOI: 10.1038/s41422-020-0282-0]

11 **de Wit E**, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc Natl Acad Sci USA* 2020; **117**: 6771-6776 [PMID: 32054787 DOI: 10.1073/pnas.1922083117]

12 **Amirian ES**, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. *One Health* 2020; **9**: 100128 [PMID: 32258351 DOI: 10.1016/j.onehlt.2020.100128]

13 **Singh AK**, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. *Diabetes Metab Syndr* 2020; **14**: 641-648 [PMID: 32428865 DOI: 10.1016/j.dsx.2020.05.018]

14 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; **383**: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

15 **WHO Solidarity Trial Consortium**, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* 2021; **384**: 497-511 [PMID: 33264556 DOI: 10.1056/NEJMoa2023184]

16 **Sterne JAC**, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: l4898 [PMID: 31462531 DOI: 10.1136/bmj.l4898]

17 **Altman DG**, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. *BMC Med Res Methodol* 2002; **2**: 3 [PMID: 11860606 DOI: 10.1186/1471-2288-2-3]

18 **Higgins JPT,** Green S, and editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011

19 **Guyatt GH**, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; **336**: 924-926 [PMID: 18436948 DOI: 10.1136/bmj.39489.470347.AD]

20 **Spinner CD**, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Effect of Remdesivir *vs* Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2020; **324**: 1048-1057 [PMID: 32821939 DOI: 10.1001/jama.2020.16349]

21 **Wang Y**, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569-1578 [PMID: 32423584 DOI: 10.1016/S0140-6736(20)31022-9]

22 **Siemieniuk R**, Rochwerg B, Agoritsas T, Lamontagne F, Leo YS, Macdonald H, Agarwal A, Zeng L, Lytvyn L, Appiah JA, Amin W, Arabi Y, Blumberg L, Burhan E, Bausch FJ, Calfee CS, Cao B, Cecconi M, Chanda D, Cooke G, Du B, Dunning J, Geduld H, Gee P, Hashimi M, Hui DS, Kabra S, Kanda S, Kawano-Dourado L, Kim YJ, Kissoon N, Kwizera A, Laake JH, Machado FR, Mahaka I, Manai H, Mino G, Nsutedu E, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Sharland M, Shen Y, Sri Ranganathan S, Souza J, Ugarte S, Venkatapuram S, Quoc Dat V, Vuyiseka D, Stegemann M, Wijewickrama A, Maguire B, Zeraatkar D, Bartoszko J, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. *BMJ* 2020; **370**: m3379 [PMID: 32887691 DOI: 10.1136/bmj.m3379]

23 **United States Food and Drug Administration.** COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19. Available from: https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized#:~:text=Today%2C%20as%20part%20of%20its,laboratory%2Dconfirmed%20COVID%2D19%2C

24 **Antinori S**, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, Gubertini G, Coen M, Magni C, Castelli A, Borghi B, Colombo R, Giorgi R, Angeli E, Mileto D, Milazzo L, Vimercati S, Pellicciotta M, Corbellino M, Torre A, Rusconi S, Oreni L, Gismondo MR, Giacomelli A, Meroni L, Rizzardini G, Galli M. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. *Pharmacol Res* 2020; **158**: 104899 [PMID: 32407959 DOI: 10.1016/j.phrs.2020.104899]

25 **Grein J**, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* 2020; **382**: 2327-2336 [PMID: 32275812 DOI: 10.1056/NEJMoa2007016]

26 **Liu Y**, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* 2020; **20**: 656-657 [PMID: 32199493 DOI: 10.1016/S1473-3099(20)30232-2]

27 **Zheng S**, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W, Wang Q, Zhang D, Liu Y, Gong R, Ma Z, Lu S, Xiao Y, Gu Y, Zhang J, Yao H, Xu K, Lu X, Wei G, Zhou J, Fang Q, Cai H, Qiu Y, Sheng J, Chen Y, Liang T. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 2020; **369**: m1443 [PMID: 32317267 DOI: 10.1136/bmj.m1443]

28 **Glasser SP**, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. *J Clin Pharmacol* 2007; **47**: 1074-1086 [PMID: 17766697 DOI: 10.1177/0091270007304776]

29 **Wysowski DK**, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. *Arch Intern Med* 2005; **165**: 1363-1369 [PMID: 15983284 DOI: 10.1001/archinte.165.12.1363]

30 **United States Food and Drug Administration.** Fact sheet for health care providers emergency use authorization (eua) of remdesivir (GS-5734™). Available from: https://www.fda.gov/media/137566/download

31 **European Medicines Agency.** Summary on compassionate use: Remdesivir. Available from: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead\_en.pdf

32 **Cheng Y**, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int* 2020; **97**: 829-838 [PMID: 32247631 DOI: 10.1016/j.kint.2020.03.005]

33 **Garrido I**, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. *Aliment Pharmacol Ther* 2020; **52**: 267-275 [PMID: 32402090 DOI: 10.1111/apt.15813]

34 **Li J**, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. *J Clin Transl Hepatol* 2020; **8**: 13-17 [PMID: 32274341 DOI: 10.14218/JCTH.2020.00019]

35 **Kim MS**, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. *PLoS Med* 2020; **17**: e1003501 [PMID: 33378357 DOI: 10.1371/journal.pmed.1003501]

36 **Piscoya A**, Ng-Sueng LF, Parra Del Riego A, Cerna-Viacava R, Pasupuleti V, Roman YM, Thota P, White CM, Hernandez AV. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. *PLoS One* 2020; **15**: e0243705 [PMID: 33301514 DOI: 10.1371/journal.pone.0243705]

37 **Enoki Y**, Igarashi Y, Watabe Y, Honma K, Suzuki Y, Hayashi Y, Hiraoka K, Taguchi K, Matsumoto K. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials. *J Glob Antimicrob Resist* 2020; **24**: 81-82 [PMID: 33307274 DOI: 10.1016/j.jgar.2020.11.022]

38 **Reddy Vegivinti CT**, Pederson JM, Saravu K, Gupta N, Barrett A, Davis AR, Kallmes KM, Evanson KW. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. *Ann Med Surg (Lond)* 2021; **62**: 43-48 [PMID: 33489115 DOI: 10.1016/j.amsu.2020.12.051]

39 **Szarpak Ł**, Dzieciątkowski T, Jaguszewski MJ, Ładny JR, Filipiak KJ. Is remdesivir important in clinical practice as a treatment of COVID-19? A study based on meta-analysis data. *Pol Arch Intern Med* 2021; **131**: 96-97 [PMID: 33231938 DOI: 10.20452/pamw.15686]

**Footnotes**

**Conflict-of-interest statement:** All authors declare having no conflicts of interest.

**PRISMA 2009 Checklist statement:** Study has been conducted as per the PRISMA 2009 checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** November 12, 2020

**First decision:** February 12, 2021

**Article in press:** February 25, 2021

**Specialty type:** Infectious diseases

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Martinez MA, Şehirli AÖ **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:** Li X

**Figure Legends**

References identified through database searching   
(n = 2289)

Full-text articles excluded, with reasons   
(n = 42)

- Review articles: 23

- In-vitro/cell culture studies: 05

- Observational studies: 05

- Simulation studies: 03

- Animal study: 01

- Case report: 5

## Included

References excluded   
(n = 2104)

Studies included in quantitative synthesis (meta-analysis)  
(n = 4)

Studies included in qualitative synthesis   
(n = 4)

Full-text articles assessed for eligibility   
(n = 46)

References screened   
(n = 2150)

References after removing duplicates  
(n = 2150)


## Identification

## Eligibility


## Screening

**Figure 1 Study selection – preferred reporting items for systematic reviews and meta-analysis flow diagram.**


A




B




C



**Figure 2 Meta-analytic summary through a random-effect model.** A: Mortality data; B: Ventilation data; C: Composite mortality and ventilation data.




**Figure 3 Meta-analytic summary of clinical recovery data through a fixed-effect model.**




**Figure 4 Meta-analytic summary of adverse events data through a random-effect model.**

A



B



**Figure 5 Meta-analytic summary through a fixed-effect model.** A: Grade 3 or 4 adverse events data; B: Serious adverse event data.

**Table 1 General and baseline characteristics of included studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Design** | **Study population** | **Total number of participants randomized/ completed** | **Age, mean** ± **SD years/median (IQR)** | **Male gender, %** | **Coexisting conditions, %** | **Severity status, %** | **Drug, dose and duration of interventions** | | **Follow-up duration in d** |
| **Remdesivir** | **Comparator** |
| Beigel *et al*[14] | Double-blind, randomized, placebo-controlled trial | Hospitalized COVID-19 patients with evidence of lower respiratory tract involvement | Total: 1062/1025; Remdesivir: 541/517; Placebo: 521/508 | Remdesivir: 58.6 ± 14.6; Placebo: 59.2 ± 15.4 | Total: 64.4; Remdesivir: 65.1; Placebo: 63.7 | Remdesivir: DM (30.8) HT (50.6); Placebo: DM (30.4); HT (50.9) | Remdesivir: MV or ECMO (24.2); Placebo: MV or ECMO (29.6) | Day 1: 200 mg iv loading dose on day 2-10: 100 mg iv daily | Placebo | 29 |
| WHO Solidarity Trial Consortium *et al*[15] | Open-labeled, randomized controlled Trial | Hospitalized COVID-19 patients | Remdesivir: 2750/2743; SC: 2725/2708 | Remdesivir: NS; SC: NS | Total: 62.9; Remdesivir: 62.2; SC: 63.7 | Remdesivir: DM (25.8); HD (20.8); Asthma (5.1); SC: DM (24.6); HD (20.9); Asthma (5.1) | Remdesivir: Ventilated (9.2); SC: Ventilated (8.6) | Day 1: 200 mg iv loading dose on day 2-10: 100 mg iv daily | SC | 28 |
| Spinner *et al*[20] | Open-labeled, randomized controlled Trial | Hospitalized moderate severity COVID-19 pneumonia patients | Total: 397/393; Remdesivir: 197/193; SC:  200/200 | Remdesivir: 56 (45-66)1; SC: 57 (45-66)1 | Remdesivir: 61; SC: 63 | Remdesivir: DM (44); HD (58); HT (44); Asthma (16); SC: HT (41); Asthma (14); DM (38); HD (54); | Remdesivir: Supplemental oxygen (13); SC: Supplemental oxygen (19) | Day 1: 200 mg iv loading dose on day 2-10: 100 mg iv daily | SC | 28 |
| Wang *et al*[21] | Double-blind, randomized, placebo-controlled trial | Severe COVID-19 with pneumonia | Total: 237/226; Remdesivir: 158/150; Placebo: 79/76 | Test: 66 (57-73)1; Placebo: 64 (53-70)1 | Remdesivir: 56; Placebo: 65 | Remdesivir: DM (25); HT (46); HD (9); Placebo: DM (21); HT (38); HD (3) | Remdesivir: Supplemental oxygen (100); Placebo: Supplemental oxygen (95) | Day 1: 200 mg iv loading dose on day 2-10: 100 mg iv daily | Placebo | 28 |

1Median (interquartile range). All patients received either remdesivir or placebo as an add-on to supportive care. DM: Diabetes mellitus; ECMO: Extracorporeal membrane oxygenation; HD: Heart disease; HT: Hypertension; IQR: Interquartile range; MV: Mechanical ventilation; NS: Not specified; SC: Supportive care; WHO: World Health Organization.

**Table 2 Risk of bias assessment as per the Revised Cochrane risk of bias tool for randomized trials**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Domain No.** | **Risk of bias domains** | **Beigel *et al*[14]** | **WHO Solidarity Trial Consortium *et al*[15]** | **Spinner *et al*[20]** | **Wang *et al*[21]** |
| 1 | Risk of bias arising from the randomization process | Low | Low | Low | Low |
| 2a | Risk of bias due to deviations from the intended interventions (effect of assignment to intervention) | Low | Low | Some concern | Low |
| 2b | Risk of bias due to deviations from the intended interventions (effect of adhering to intervention) | Low | Low | Low | Low |
| 3 | Missing outcome data | Low | Low | Low | Low |
| 4 | Risk of bias in measurement of the outcome | Low | Low | Low | Low |
| 5 | Risk of bias in selection of the reported result | Low | Low | Low | Low |
| -- | Overall risk of bias assessment | Low | Low | Some concerns | Low |

WHO: World Health Organization.

**Table 3 Quality assessment for efficacy and safety parameters as per the GRADE approach**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **No. of studies (design)** | **Limitation** | **Inconsistency** | **Indirectness** | **Imprecision** | **Publication bias** | **Quality** | **RR (95%CI)** |
| Mortality | | | | | | | |
| Four (RCT) | No serious limitations | Serious inconsistency (*I*2 = 59%) | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 0.83 (0.57-1.20) |
| Ventilation | | | | | | | |
| Four (RCT) | No serious limitations | Serious inconsistency (*I*2 = 77%) | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 0.69 (0.41-1.18) |
| Composite Mortality and ventilation | | | | | | | |
| Four (RCT) | No serious limitations | Serious inconsistency (*I*2 = 78%) | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 0.80 (0.58-1.11) |
| Clinical recovery | | | | | | | |
| Three (RCT) | No serious limitations | No serious inconsistency | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 1.10 (1.04-1.16) |
| Adverse event | | | | | | | |
| Three (RCT) | No serious limitations | Serious inconsistency (*I*2 = 77%) | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 1.05 (0.86-1.27) |
| Grade 3 or 4 adverse event | | | | | | | |
| Three (RCT) | No serious limitations | No serious inconsistency | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 0.88 (0.79-0.99) |
| Serious adverse event | | | | | | | |
| Three (RCT) | No serious limitations | No serious inconsistency | No serious indirectness | No serious imprecision | Asymmetric Funnel plot | Moderate | 0.75 (0.63-0.89) |

CI: Confidence interval; RCT: Randomized controlled trial; RR: Risk ratio.

**Table 4 Sensitivity analysis of efficacy and safety outcomes based on the risk of bias assessment and study design**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **All studies** | | **Sensitivity analysis**  **(risk of bias assessment)** | | **Sensitivity analysis (study design)** | |
| **RR (95%CI)** | ***I*2** | **RR (95%CI)** | ***I*2** | **RR (95%CI)** | ***I*2** |
| Mortality | 0.83 (0.57-1.20) | 59 | 0.83 (0.55-1.26) | 73 | 0.74 (0.38-1.44) | 65 |
| Ventilation | 0.69 (0.41-1.18) | 77 | 0.73 (0.42-1.27) | 83 | 0.57 (0.41-0.77) | 00 |
| Composite mortality and ventilation | 0.80 (0.58-1.11) | 78 | 0.83 (0.60-1.16) | 84 | 0.69 (0.55-0.86) | 10 |
| Clinical recovery | 1.10 (1.04-1.16) | 00 | 1.10 (1.02-1.18) | 00 | 1.10 (1.02-1.18) | 00 |
| Adverse event | 1.05 (0.86-1.27) | 77 | 0.94 (0.86-1.02) | 00 | 0.94 (0.86-1.02) | 00 |
| Grade 3 or 4 adverse event | 0.89 (0.80-0.99) | 00 | 0.87 (0.71-1.07) | 10 | 0.87 (0.71-1.07) | 10 |
| Serious adverse event | 0.75 (0.63-0.90) | 00 | 0.76 (0.64-0.92) | 00 | 0.76 (0.64-0.92) | 00 |

CI: Confidence interval; RR: Risk ratio.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**